HHV6 reactivation is an important risk factor for poor outcomes in myeloablative, but not in non-myeloablative treated allogeneic HSCT patients
2009
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI